Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12-month consensus price objective of $4.50 for the company and are anticipating that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also given ContraVir Pharmaceuticals an industry rank of 129 out of 265 based on the ratings given to related companies.
Separately, Maxim Group reiterated a “buy” rating and set a $4.00 target price on shares of ContraVir Pharmaceuticals in a research report on Thursday, October 13th.
Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in ContraVir Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 915,369 shares of the biopharmaceutical company’s stock worth $952,000 after buying an additional 73,135 shares in the last quarter. Teachers Advisors Inc. raised its position in ContraVir Pharmaceuticals by 95.2% in the second quarter. Teachers Advisors Inc. now owns 289,919 shares of the biopharmaceutical company’s stock worth $1,102,000 after buying an additional 141,368 shares in the last quarter. Finally, Prospera Financial Services Inc raised its position in ContraVir Pharmaceuticals by 8.5% in the third quarter. Prospera Financial Services Inc now owns 193,800 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 15,250 shares in the last quarter. 4.98% of the stock is currently owned by hedge funds and other institutional investors.
ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at 1.43 on Friday. The company has a 50-day moving average price of $1.51 and a 200-day moving average price of $1.45. The firm’s market cap is $85.72 million. ContraVir Pharmaceuticals has a 12-month low of $0.81 and a 12-month high of $2.65.
About ContraVir Pharmaceuticals
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.
Get a free copy of the Zacks research report on ContraVir Pharmaceuticals (CTRV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com